Future therapies for pemphigus vulgaris: Rituximab and beyond

Journal of the American Academy of Dermatology
Amy HuangJacob Levitt

Abstract

The conventional treatment for patients with pemphigus vulgaris (PV) centers on global immunosuppression, such as the use of steroids and other immunosuppressive drugs, to decrease titers of antidesmoglein autoantibodies responsible for the acantholytic blisters. Global immunosuppressants, however, cause serious side effects. The emergence of anti-CD20 biologic medications, such as rituximab, as an adjunct to conventional therapy has shifted the focus to targeted destruction of autoimmune B cells. Next-generation biologic medications with improved modes of delivery, pharmacology, and side effect profiles are constantly being developed, adding to the diversity of options for PV treatment. We review promising monoclonal antibodies, including veltuzumab, obinutuzumab (GA-101), ofatumumab, ocaratuzumab (AME-133v), PRO131921, and belimumab.

References

Nov 4, 2004·Journal of the American Academy of Dermatology·Lynne H Morrison
Aug 2, 2005·Cancer Treatment Reviews·Eva Kimby
Oct 17, 2006·International Journal of Dermatology·Mitra M FatourechiLawrence E Gibson
Oct 27, 2006·The New England Journal of Medicine·A Razzaque AhmedMarshall R Posner
Dec 28, 2006·Journal of the American Academy of Dermatology·Julia E GravesMichael P Heffernan
Aug 10, 2007·The New England Journal of Medicine·Pascal JolyPhilippe Musette
Jun 20, 2008·The Journal of Investigative Dermatology·Rüdiger EmingMichael Hertl
Aug 19, 2008·Current Oncology Reports·Manzurul A Sikder, Jonathan W Friedberg
Nov 11, 2008·The Journal of Investigative Dermatology·Giovanna Zambruno, Luca Borradori
Jun 9, 2009·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Enno SchmidtArno Kromminga
Mar 31, 2010·Seminars in Hematology·Tom van Meerten, Anton Hagenbeek
Apr 7, 2010·Leukemia & Lymphoma·Myron S Czuczman, Stephanie A Gregory
Oct 26, 2010·Current Opinion in Immunology·Anne Davidson
Jun 11, 2011·Best Practice & Research. Clinical Haematology·Andrew R Rezvani, David G Maloney
Jan 10, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andres Forero-TorresKristen N Ganjoo
Nov 13, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Karissa M JohnstonStuart Peacock
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
Feb 7, 2014·JAMA Dermatology·Kara HeelanNeil H Shear
Aug 22, 2014·The Journal of Investigative Dermatology·Christoph M HammersJohn R Stanley
Mar 17, 2015·Journal of Cutaneous Medicine and Surgery·Kara HeelanNicole Mittmann

❮ Previous
Next ❯

Citations

Dec 2, 2017·The British Journal of Dermatology·K E HarmanP D Yesudian
Jan 10, 2018·Clinical Reviews in Allergy & Immunology·Robert PollmannMichael Hertl
Apr 13, 2019·Dermatologic Therapy·Cahit Yavuz
Aug 1, 2019·Anais Brasileiros De Dermatologia·Adriana Maria PorroMilvia Maria Simões E Silva Enokihara
Oct 6, 2018·Dermatologic Therapy·Camilla LoiFederico Bardazzi
Aug 30, 2020·American Journal of Clinical Dermatology·Emily M Altman
May 12, 2017·Nature Reviews. Disease Primers·Michael KasperkiewiczMasayuki Amagai
May 17, 2018·Applied Microbiology and Biotechnology·Yafang LuBuchang Zhang
Jul 7, 2018·Journal of Immunology Research·Matteo SaccucciAntonella Polimeni
Mar 20, 2019·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·N van BeekE Schmidt
Jan 1, 2019·Anais Brasileiros De Dermatologia·Adriana Maria PorroSilva Enokihara

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.